{"groups":[{"description":"Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"FG000","title":"Trifluridine and Tipiracil or Regorafenib"},{"description":"Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"FG001","title":"Sotorasib 240 mg + Panitumumab"},{"description":"Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"FG002","title":"Sotorasib 960 mg + Panitumumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"33"}],"type":"Participants continuing trial"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Withdrawal of consent from trial"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"18"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"53"},{"groupId":"FG002","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"53"},{"groupId":"FG002","numSubjects":"53"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with previously treated metastatic colorectal cancer (CRC) with the kirsten rat sarcoma (KRAS) p.G12C mutation were enrolled and randomized 1:1:1 to receive either sotorasib 240 mg daily (QD) and panitumumab, sotorasib 960 mg QD and panitumumab, or investigator's choice (trifluridine and tipiracil, or regorafenib). Investigator's choice was declared prior to randomization.","recruitmentDetails":"Participants were enrolled at 67 trial centers across Asia, Europe, North America, and Australia starting on 19 April 2022. The primary analysis results presented here, for primary analysis presented here are based on data cut-off (DCO) 19 June 2023. The trial is still ongoing."}